Specialized Medical H1 2025 Profit Falls 34% Despite Clinic Expansion

Riyadh, Saudi Arabia — Specialized Medical H1 2025 profit dropped 34.1% year-on-year to SAR 66 million, despite a rise in revenue to SAR 748.9 million, according to a Tadawul filing. The decline reflects the financial effects of the company’s shift away from long-term care and its aggressive clinic expansion strategy.

Revenue Growth from New Clinics

Revenue rose steadily as the company opened 41 new outpatient clinics in H1, including 21 in Q2. These, along with the maturing 20 clinics launched in Q1 and the ramp-up of the SMC 2 facility, fueled top-line growth.

In Q2, revenue increased 6.6% year-on-year to SAR 380 million and rose 3% from Q1. However, net profit fell 28.6% to SAR 36.4 million due to higher operating costs. Quarter-on-quarter, profit improved by 22.7%.

Profit Under Pressure Amid Strategic Pivot

The drop in Specialized Medical H1 2025 profit stems from the company’s shift in strategy. Exiting long-term care led to higher staff retention costs, pre-opening expenses for clinics, and one-time rebranding and IPO-related charges.

Gross profit declined 4.7% to SAR 196.2 million, while operating profit dropped 29% to SAR 89.3 million. Total comprehensive income fell 36.3% to SAR 65.3 million. Earnings per share slipped to SAR 0.26 from SAR 0.40 in H1 2024.

Despite this, shareholders’ equity grew 13.7% to SAR 992.4 million, showing capital strength.

Looking Ahead

SMC remains focused on growing its outpatient and inpatient services. Management expects this service mix shift to deliver higher margins and long-term profit stability.

THE SAUDI STANDARD’S VIEW: Profit Decline Reflects Strategic Investment, Not Weakness

SMC’s 34% profit decline in H1 2025 reflects the cost of shifting away from long-term care and investing in outpatient services. However, the 4.1% revenue growth to SAR 748.9 million—driven by new clinics and the SMC 2 ramp-up—shows the company’s expanding reach and alignment with Vision 2030.

The lower profits stem from temporary costs: pre-opening expenses, staff adjustments, and IPO planning. Yet, these investments support a new strategy that aims for stronger margins and service quality over time.

Importantly, shareholder equity rose 13.7%, signaling continued investor trust. The profit rebound in Q2, along with a reaffirmed focus on outpatient care, suggests that the company is already stabilizing.

In conclusion, SMC’s results reflect a transition period. As Saudi Arabia shifts toward preventive and outpatient healthcare, the company’s new strategy places it in a strong position to meet demand and deliver sustainable growth.